SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): October 26, 2005
NOVAVAX, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
DELAWARE
(State or Other Jurisdiction
of
Incorporation)
|
|
0-26770
(Commission File Number) |
| |
|
|
508 Lapp
Road,
Malvern, Pennsylvania
|
|
19355 |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
484-913-1200
Registrant’s telephone number, including area code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
Novavax,
Inc. (“Novavax”) issued a press release on October 26, 2005 announcing that certain
holders of $6.0 million face amount of Novavax’s 4.75% senior convertible notes due July 15, 2009
(the “Notes”) exercised their optional conversion right to convert such Notes. A copy of the press
release dated October 26, 2005 is being filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1
— Press release issued by Novavax dated October 26, 2005.